Olema Pharmaceuticals, Inc. (OLMA)
$
5.3
+0.34 (6.42%)
Key metrics
Financial statements
Free cash flow per share
-1.4595
Market cap
362.6 Million
Price to sales ratio
0
Debt to equity
0.0030
Current ratio
15.2188
Income quality
0.9685
Average inventory
0
ROE
-0.4231
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies specifically targeting women's cancers. The company’s lead product candidate, OP-1250, acts as an estrogen receptor (ER) antagonist and a selective ER degrader, currently undergoing a Phase 1/2 clinical trial aimed at treating recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The diluted EPS is -$2.20 accounting for potential share dilution, while the weighted average number of shares outstanding is 58,743,522.00 highlighting the company's shareholder base. Additionally, Olema Pharmaceuticals incurred an income tax expense of $0.00 indicating its tax obligations within the biopharmaceutical landscape. The cost of revenue for the company stands at $393,000.00 showcasing its production and operational expenses, and the weighted average number of diluted shares outstanding is 58,743,522.00 reflecting potential dilution effects on its financial performance. In the context of investment opportunities, the stock is affordable at $5.30 making it suitable for budget-conscious investors. It has an average trading volume of 903,840.00 indicating moderate liquidity in the market. With a market capitalization of $362,632,890.00 the company is classified as a small-cap player, positioning it effectively within the industry. Olema Pharmaceuticals is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth in the therapeutic arena. This strategic focus on women’s cancers underscores Olema's commitment to bringing novel therapies to market, thereby enhancing its significance in the healthcare sector.
Is Olema Pharmaceuticals, Inc. (OLMA) a good investment?
Investing in Olema Pharmaceuticals, Inc. (OLMA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Olema Pharmaceuticals, Inc. (OLMA)'s stock forecast?
Analysts predict Olema Pharmaceuticals, Inc. stock to fluctuate between $2.86 (low) and $16.62 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Olema Pharmaceuticals, Inc.'s market capitalization?
As of 2025-05-29, Olema Pharmaceuticals, Inc.'s market cap is $362,632,890, based on 68,421,300 outstanding shares.
How does Olema Pharmaceuticals, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Olema Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Olema Pharmaceuticals, Inc. (OLMA) stock?
To buy Olema Pharmaceuticals, Inc. (OLMA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for OLMA. Place an order (Market, Limit, etc.).
What is the best time to invest in Olema Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Olema Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.20 | Growth: 2.80%.
Where can I find Olema Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.olema.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Olema Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Olema Pharmaceuticals, Inc. stock?
All-time high: $54.88 (2021-02-11) | All-time low: $2 (2022-05-09).
What are the key trends affecting Olema Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
zacks.com
The consensus price target hints at a 386.4% upside potential for Olema Pharmaceuticals (OLMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
globenewswire.com
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 433.1% in Olema Pharmaceuticals (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
The heavy selling pressure might have exhausted for Olema Pharmaceuticals (OLMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
seekingalpha.com
Olema Pharmaceuticals's palazestrant shows promise in late-stage trials for metastatic breast cancer, with potential FDA approval and commercial launch by 2027. Strong liquidity with $139.5 million in cash and $294.6 million in marketable securities, providing a cash runway of 4-4.5 years. Despite competition in the SERD space, OLMA's valuation is low at $200 million, suggesting potential for significant upside.
globenewswire.com
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a poster highlighting preclinical anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and non-small cell lung cancer models in a late-breaking session at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25-30 in Chicago, Illinois. Poster Presentation Details Title: OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models Poster/Abstract: LB166 Session: Late-Breaking Research: Tumor Biology 2 Date/Time: April 28, 2025, from 9:00am-12:00pm CT / 10:00am-1:00pm ET Presenter: Dr. Gopinath S.
See all news
